BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks

  • BioCryst Pharmaceuticals Inc BCRX has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in hereditary angioedema (HAE) attacks patients.
  • The HAE patients who were randomized to receive 150 mg of oral, once-daily Orladeyo at the start of the trial had an 80% average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. 
  • Median attack rates also decreased from 2.7 attacks/month at baseline to 0.0 attacks per month in 16 of 17 months through the same period.
  • Orladeyo was generally well-tolerated during the treatment period, with fewer drug-related adverse events reported in part 3 (weeks 49-96) as compared to part 1 (weeks 0-24) and part 2 (weeks 25-48). 81% of the patients who entered part 3 completed the trial.
  • The new data also showed a reduction in on-demand medication use in HAE patients treated with Orladeyo.
  • Orladeyo demonstrated consistently low attack rates in adolescent patients (ages 12-17), with the mean attack rate at week 4 was 0.4 attacks/month, which was generally sustained through week 48.
  • Median attack rates in these adolescents were 0.0 attacks/month throughout the 48 weeks of treatment.
  • Over 70% of patients were attack-free in weeks 4 to 48.
  • Price Action: BCRX shares are up 0.85% at $16.50 premarket on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefshereditary angioedema
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!